Hersintuzumab is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ErbB2). By specifically binding to the extracellular domain of HER2, it blocks downstream proliferative signaling pathways (e.g., PI3K/Akt) and mediates antibody-dependent cellular cytotoxicity (ADCC), making it widely used to research therapeutic strategies for HER2-positive malignancies like breast and gastric cancers.
Target-Kategorie:
EGFR
T9901A-1325
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
